Keapstone Therapeutics

Keapstone Therapeutics is a biotech startup founded in 2017, with a focus on developing drugs targeting the Nrf2 signalling pathway (KEAP1 inhibitors) for Parkinson’s and Motor Neuron Disease (MND). Co-founded by the University of Sheffield, Parkinson’s UK, Dr. Richard Mead, and Prof. Pamela Shaw of the Sheffield Institute for Translational Neuroscience (SITraN), Keapstone leverages world-leading research with funding and expertise from Parkinson’s UK. It also collaborates with consultants and discovery partners to tap into extensive drug development expertise. With a potential impact on over 130,000 people in the UK affected by these conditions, Keapstone's innovative approach holds promise for addressing significant unmet medical needs.